Biological E Limited
- All
- News
-
Hyderabad-Based Biological E Gets Approval For Pneumococcal Conjugate Vaccine
Hyderabad-based pharmaceutical and vaccine manufacturer Biological E Limited (BE), on Friday announced that its 14-valent paediatric Pneumococcal Conjugate Vaccine has received approval for manufacture and commercialisation in India.
-
Biological E Aims To Produce 100 Million Doses Of Corbevax Every Month From Feb 2022
Biological E. Limited plans to complete production at a rate of 75 million doses of its COVID-19 vaccine Corbevax per month, anticipating over 100 million doses per month from February 2022.
-
Hyderabad's Biological E Expects To Rollout Corbevax Covid Vaccine By November-End
Biological E. Limited (BE) is expecting its COVID-19 vaccine Corbevax to be rolled out by the end of November even as the city-based firm is getting ready with 100 million doses for the launch, Mahima Datla, Managing Director, BE said on Monday.
-
No Scientific Body Suggests Kids' Vaccination For School Opening: Centre
Hyderabad-based Biological E Limited has been given permission to conduct the phase two/three clinical trial of its indigenously developed COVID-19 vaccine on children and adolescents aged between five and 18 years with certain conditions.
-
US College Ties Up With Indian Firm For Covid Vaccine Production
In the race to find a cure for the coronavirus infection, Texas-based Baylor College of Medicine (BCM) has entered into a licensing agreement with Indian pharmaceutical company Biological E Limited (BE) for the development of a safe, effective and affordable vaccine.
-
Hyderabad-Based Biological E Gets Approval For Pneumococcal Conjugate Vaccine
Hyderabad-based pharmaceutical and vaccine manufacturer Biological E Limited (BE), on Friday announced that its 14-valent paediatric Pneumococcal Conjugate Vaccine has received approval for manufacture and commercialisation in India.
-
Biological E Aims To Produce 100 Million Doses Of Corbevax Every Month From Feb 2022
Biological E. Limited plans to complete production at a rate of 75 million doses of its COVID-19 vaccine Corbevax per month, anticipating over 100 million doses per month from February 2022.
-
Hyderabad's Biological E Expects To Rollout Corbevax Covid Vaccine By November-End
Biological E. Limited (BE) is expecting its COVID-19 vaccine Corbevax to be rolled out by the end of November even as the city-based firm is getting ready with 100 million doses for the launch, Mahima Datla, Managing Director, BE said on Monday.
-
No Scientific Body Suggests Kids' Vaccination For School Opening: Centre
Hyderabad-based Biological E Limited has been given permission to conduct the phase two/three clinical trial of its indigenously developed COVID-19 vaccine on children and adolescents aged between five and 18 years with certain conditions.
-
US College Ties Up With Indian Firm For Covid Vaccine Production
In the race to find a cure for the coronavirus infection, Texas-based Baylor College of Medicine (BCM) has entered into a licensing agreement with Indian pharmaceutical company Biological E Limited (BE) for the development of a safe, effective and affordable vaccine.
